# EDGAR Filing Document

**Accession Number:** 0001751912
**File Stem:** 0001104659-26-002130
**Filing Date:** 2026-1
**Character Count:** 4042
**Document Hash:** 300554a28cdc495e39bb6eb2b4e2a1cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-002130.hdr.sgml**: 20260108

**ACCESSION NUMBER**: 0001104659-26-002130

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260108

**FILED AS OF DATE**: 20260108

**DATE AS OF CHANGE**: 20260108

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NERVGEN PHARMA CORP.
- **CENTRAL INDEX KEY:** 0001751912
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43048
- **FILM NUMBER:** 26519704

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 1703 - 595 BURRARD STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V7X 1J1
- **BUSINESS PHONE:** 6047225361

**MAIL ADDRESS:**
- **STREET 1:** SUITE 1703 - 595 BURRARD STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V7X 1J1

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 <br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2026**

Commission File Number: **001-43048**

**NERVGEN PHARMA CORP.**<br> (Exact name of Registrant as specified in its charter)

**N/A**<br> (Translation of Registrant's name)

**112-970 Burrard Street, Unit 1290<br> Vancouver, British Columbia, Canada V6Z 2R4<br> Telephone: (778) 731-1711**<br> (Address and telephone number of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ◻ Form 40-F ⌧

**INCORPORATION BY REFERENCE**

Exhibit 99.1 of this Form 6-K is incorporated by reference into the registrant's Registration Statement on [Form F-10 (File No. 333-292197)](https://www.sec.gov/Archives/edgar/data/1751912/000110465925122026/tm2532520-1_f10.htm).

**DOCUMENTS INCLUDED AS PART OF THIS REPORT**

---

| | |
|:---|:---|
| **Exhibit** |  |
| [99.1](tm262534d1_ex99-1.htm) | [Material Change Report, dated January 8, 2026](tm262534d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **<br> NERVGEN PHARMA CORP.** | **<br> NERVGEN PHARMA CORP.** |
| Date: January 8, 2026 | By: | /s/ William J. Adams |
|  |  | Name: William J. Adams |
|  |  | Title: Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Form 51-102F3**

**MATERIAL CHANGE REPORT**

### Item 1. **Name and Address of Reporting Issuer** 
NervGen Pharma Corp. ("**NervGen**" or the "**Company**")

112-970 Burrard Street

Unit 1290

Vancouver, BC V6Z 2R4

### Item 2. **Date of Material Changes** 
January 8, 2026

### Item 3. **News Releases** 
A news release announcing the material change was disseminated on January 8, 2026 through GlobeNewswire distribution network, and a copy was filed on NervGen's SEDAR+ profile at www.sedarplus.ca.

### Item 4. **Summary of Material Changes** 
On January 8, 2026, the Company announced the Company's common shares have been approved for listing on Nasdaq.

### Item 5. **Full Description of Material Changes** 
On January 8, 2026, the Company announced the Company's common shares have been approved for listing on Nasdaq. NervGen's common shares began trading on Nasdaq as of January 8, 2026, under the symbol "NGEN."

Item 6. **Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

### Item 7. **Omitted Information** 
No information has been omitted on the basis that it is confidential information.

### Item 8. **Executive Officer** 
William Adams, Chief Financial Officer

112-970 Burrard Street

Unit 1290

Vancouver, BC V6Z 2R4

### Item 9.  **Date of Report** 
January 8, 2026.